Literature DB >> 2457766

Evolving myocardial infarction in the rat in vivo: an inappropriate model for the investigation of drug-induced infarct size limitation during sustained regional ischaemia.

D J Hearse1, V Richard, D M Yellon, J G Kingma.   

Abstract

Despite the rat heart having very low collateral flow, there are many reports of pharmacological limitation of infarct size in rats with permanent coronary occlusion. Investigating possible artefacts, cardiac function was measured in isolated rat hearts (n = 12/group) 1, 2, 4, 6, 12, 18, 24, or 48 h after permanent coronary occlusion. In sham operated controls, cardiac output was 63.8 +/- 3.8 ml/min; in rats with occlusion this fell to 37.7 +/- 3.3 ml/min after 1 h of occlusion and did not increase during the 48 h of study. Lumen areas, areas of underperfusion, and minimum wall thickness were unchanged after 4 h of occlusion. Between 4 and 12 h, substantial wall thinning occurred (midinfarct wall thickness decreased from 3.69 +/- 0.24 mm to 2.01 +/- 0.16 mm). After 12 h of occlusion, wall thinning and expansion of the infarct increased lumen volume by three- to fourfold. Wall thinning resulted in a progressive decrease in the volume of the zone of underperfusion (which decreased by almost 30% over 48 h). Tetrazolium negative tissue was not evident in the first 4 h of occlusion but by 12 h, 85.0 +/- 2.6% of the underperfused tissue was necrotic. Gross examination of sections often indicated apparently tetrazolium positive tissue within the zone of underperfusion. Microscopic examination of histological sections revealed this tissue to be necrotic but, in contrast to the tetrazolium negative tissue within the zone of underperfusion, not yet subject to white cell infiltration. "Apparent" infarct size limitation in the rat heart might be due to: (1) incorrect designation of tissue as tetrazolium positive within the severely ischaemic zone of underperfusion; (2) inappropriately equating the zone of underperfusion (measured at the end of ischaemia) to the risk zone (measured at the onset of ischaemia); (3) the possibility that some drugs might affect white cell infiltration, tetrazolium staining characteristics, wall thinning, and tissue remodelling.

Entities:  

Mesh:

Year:  1988        PMID: 2457766

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  Inhibition of L-carnitine biosynthesis and transport by methyl-γ-butyrobetaine decreases fatty acid oxidation and protects against myocardial infarction.

Authors:  E Liepinsh; M Makrecka-Kuka; J Kuka; R Vilskersts; E Makarova; H Cirule; E Loza; D Lola; S Grinberga; O Pugovics; I Kalvins; M Dambrova
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

2.  Antiarrhythmic and antinecrotic effects of yohimbine stereoisomers in rats during coronary occlusion and reperfusion.

Authors:  W Bernauer
Journal:  Basic Res Cardiol       Date:  1990 Mar-Apr       Impact factor: 17.165

3.  Chronic administration of allopurinol fails to exert any cardioprotective effect in rats submitted to permanent coronary artery ligation.

Authors:  F Boucher; J de Leiris
Journal:  Basic Res Cardiol       Date:  1991 May-Jun       Impact factor: 17.165

4.  Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: studies with bosentan, a mixed ETA-ETB antagonist.

Authors:  V Richard; N Kaeffer; M Hogie; C Tron; T Blanc; C Thuillez
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

5.  Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.

Authors:  Masashi Mizuno; Atsushi Kuno; Toshiyuki Yano; Takayuki Miki; Hiroto Oshima; Tatsuya Sato; Kei Nakata; Yukishige Kimura; Masaya Tanno; Tetsuji Miura
Journal:  Physiol Rep       Date:  2018-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.